Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Rhea-AI Summary
Alterity Therapeutics (NASDAQ: ATHE) received positive feedback from a Type C meeting with the FDA on March 30, 2026, supporting its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA).
The FDA provided written support for the company’s clinical pharmacology and non-clinical development elements. Alterity said it will seek agreement on CMC and the Phase 3 trial design, with an End-of-Phase 2 meeting on track for mid-year 2026.
Positive
- FDA gave written support for clinical pharmacology elements
- FDA gave written support for non-clinical development elements
- End-of-Phase 2 meeting remains on track for mid-year 2026
Negative
- CMC agreement with FDA is still pending
- Final Phase 3 trial design approval with FDA has not been reached
Key Figures
Market Reality Check
Peers on Argus
Biotech peers show mixed moves, with some up and others down, and momentum scan peers split between gains and losses, indicating ATHE’s setup appears more stock-specific than sector-driven.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 09 | Phase 2 data update | Positive | +4.4% | Presented Phase 2 ATH434-201 data with strong efficacy and biomarker signals. |
| Sep 15 | Phase 2 data update | Positive | -5.0% | Presented promising Phase 2 ATH434 data showing disease-modifying effects and tolerability. |
| Jul 28 | Topline Phase 2 data | Positive | -14.8% | Reported positive topline data from open-label Phase 2 trial with reduced progression. |
| Apr 28 | Phase 2 results update | Positive | -0.0% | Presented ATH434-201 results showing significant efficacy and good tolerability in MSA. |
| Apr 10 | Phase 2 data update | Positive | +3.7% | Shared encouraging Phase 2 data demonstrating clinically meaningful efficacy and biomarker effects. |
Positive ATH434 clinical updates often met with mixed or negative price reactions, showing more divergences than alignments.
Over the past year, Alterity has repeatedly reported positive Phase 2 data for ATH434 in MSA across major neurology and movement-disorder meetings. These updates highlighted clinically meaningful efficacy, biomarker effects, and favorable safety, yet same-day reactions ranged from a 14.81% decline to a 4.41% gain. The current FDA Type C feedback on the Phase 3 program builds on this Phase 2 foundation and continues the transition toward a pivotal study for ATH434.
Historical Comparison
Clinical-trial news for ATH434 has led to an average -2.34% move, with several positive data updates still met by selling pressure or muted reactions.
Clinical updates show a steady progression from multiple Phase 2 readouts with efficacy and biomarker data toward regulatory interactions supporting a pivotal Phase 3 program.
Market Pulse Summary
This announcement highlights FDA Type C feedback that supports key clinical pharmacology and non‑clinical components of the ATH434 Phase 3 program in MSA, with an End‑of‑Phase 2 meeting targeted for mid‑2026. It extends a sequence of positive Phase 2 data and late‑stage planning. Investors may watch for upcoming CMC alignment, final Phase 3 trial design, and regulatory meeting outcomes as critical milestones for translating ATH434’s prior efficacy signals into a pivotal study.
Key Terms
clinical pharmacology medical
chemistry, manufacturing, and controls (cmc) regulatory
pivotal trial technical
end-of-phase 2 meeting regulatory
AI-generated analysis. Not financial advice.
Alignment reached on key elements of ATH434 Phase 3 development program
MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA).
The Type C Meeting is part of a multidisciplinary strategy to seek alignment with the FDA on readiness to initiate a Phase 3 pivotal trial in MSA. Alterity received written feedback supporting its plans related to the clinical pharmacology and non-clinical development elements of the program.
“This meeting confirms alignment with the FDA in two key disciplines and represents an important step toward initiation of the Phase 3 program,” said David Stamler, M.D., Chief Executive Officer of Alterity. “In addition, we will also be seeking agreement with the FDA on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design. Today’s favorable outcome sets the stage for our future discussions, culminating in an End-of-Phase 2 meeting that remains on track for mid-year 2026.”
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by the Board of Alterity Therapeutics Limited.
Contacts:
Investors:
Tara Speranza
Head of Investor Relations and Communications
tsperanza@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
FAQ
What did Alterity announce about the ATH434 Phase 3 program (ATHE) on March 30, 2026?
Which parts of the ATH434 program did the FDA support, and what remains unresolved for ATHE?
What is the expected timing for Alterity's End-of-Phase 2 meeting for ATH434 (ATHE)?
How does the FDA Type C meeting outcome affect the ATH434 Phase 3 start for ATHE?
Does the March 30, 2026 update from Alterity (ATHE) include clinical results or financial details?
